bosentan anhydrous has been researched along with Hyperemia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Böhm, F; Brismar, K; Gonon, A; Pernow, J; Rafnsson, A; Settergren, M | 1 |
1 trial(s) available for bosentan anhydrous and Hyperemia
| Article | Year |
|---|---|
The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial.
Topics: Aged; Albuminuria; Antihypertensive Agents; Bosentan; Brachial Artery; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Endothelin Receptor Antagonists; Endothelium, Vascular; Female; Humans; Hyperemia; Male; Microvessels; Middle Aged; Peripheral Vascular Diseases; Severity of Illness Index; Sulfonamides; Vasodilation | 2012 |